SCHEMBL5748764

SCHEMBL5748764

Cc1nc2ccccc2c(=O)n1CCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
GFER P55789 1/20 0.82
CASR P41180 5/20 0.72
SMN1; SMN2 Q16637 4/20 0.69
ALDH1A1 P00352 1/20 0.69
TSHR P16473 3/20 0.68
LMNA P02545 4/20 0.62
KDM4E B2RXH2 2/20 0.62
NPY1R P25929 1/20 0.62
HTT P42858 1/20 0.62
NPY2R P49146 1/20 0.62
GAA P10253 2/20 0.61
HSD17B10 Q99714 2/20 0.61
PLA2G1B P04054 1/20 0.61
ATG4B Q9Y4P1 1/20 0.61
APP P05067 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2C9 P11712 1/20 0.58
HDAC1 Q13547 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15302491 0.85 MEN1 (0.74) MEN1KMT2AGFERCASRSMN1; SMN2
SCHEMBL12963486 0.84 MEN1 (0.73) MEN1KMT2AGFERSMN1; SMN2ALDH1A1
SCHEMBL5777984 0.84 CASR (1.00) MEN1KMT2AGFERCASRSMN1; SMN2
SCHEMBL31037456 0.83 MEN1 (0.71) MEN1KMT2AGFERCASRSMN1; SMN2
SCHEMBL1544971 0.83 MEN1 (0.71) MEN1KMT2AGFERCASRSMN1; SMN2
SCHEMBL3828558 0.83 TSHR (0.83) MEN1KMT2AGFERCASRSMN1; SMN2
SCHEMBL26079023 0.82 MEN1 (0.70) MEN1KMT2AGFERCASRSMN1; SMN2
SCHEMBL2627967 0.82 MEN1 (0.69) MEN1KMT2AGFERCASRSMN1; SMN2
SCHEMBL5921199 0.82 CASR (0.75) MEN1KMT2AGFERCASRSMN1; SMN2
SCHEMBL5921364 0.82 CASR (0.85) MEN1KMT2AGFERCASRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558260-A4 QUINAZOLINONE COMPOUNDS AS CALCILYTICS NPS PHARMA INC (US) 2006-10-25 EP disclosed
US-20060052345-A1 Quinazolinone compounds as calcilytics NPS PHARMACEUTICALS, INC. (US) 2006-03-09 US disclosed
CN-1708306-A Quinazolinone compounds as calcilytics NPS PHARMA INC (US) 2005-12-14 CN disclosed
EP-1558260-A2 QUINAZOLINONE COMPOUNDS AS CALCILYTICS NPS PHARMACEUTICALS, INC. (US) 2005-08-03 EP disclosed
WO-2004041755-A2 QUINAZOLINONE COMPOUNDS AS CALCILYTICS NPS PHARMACEUTICALS, INC. (US) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052345-A1 Quinazolinone compounds as calcilytics CALCR, CALCRL, CASR MEN1 840/4885KMT2A 4854/4885GFER 3259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.